Navigation Links
Arthritis Foundation Announces Appointment of John Vernachio As Vice President of Research
Date:4/15/2013

ATLANTA, April 15, 2013 /PRNewswire-USNewswire/ -- The Arthritis Foundation announces the appointment of John Vernachio , Ph.D. as vice president of research effective April 15. In his new role he will provide leadership and direction to further the Arthritis Foundation research program and the organization's commitment to finding a cure and better, safer treatments for the nation's leading cause of disability. Vernachio will succeed Dr. John Hardin , who will assume a new role within the organization developing and implementing flagship initiatives in osteoarthritis.

(Photo: http://photos.prnewswire.com/prnh/20130415/DC95154 )

" John Vernachio is a world-class scientist and director in biotechnology with a proven track record," says Arthritis Foundation Chief Mission Officer, Jennifer Griffiths , Ph.D.  "I am confident that under his leadership the Arthritis Foundation will continue its legacy in driving targeted research initiatives that will push us toward a cure."

Vernachio brings to the Arthritis Foundation extensive research leadership and expertise, serving as a researcher and technical director in the biotechnology sector for more than 20 years. Most recently, he served as vice president of biology for Inhibitex, Inc.  Earlier, he held supervisory and leadership roles in several biotechnology companies including Baxter Healthcare and Valentis, Inc.  In addition, he is an author on over 20 peer-reviewed scientific articles, numerous scientific presentations and is a co-inventor on 10 patent applications.

A graduate of the University of Vermont, Vernachio earned a Bachelor of Science degree in Animal Science in 1984. He received a doctorate in biochemistry with a concentration in immunology and molecular biology in 1989 from Johns Hopkins University and completed his post-doctoral training in the Department of Immunology at The Research Institute of Scripps Clinic in San Diego in 1991.

About the Arthritis Foundation

Striking one in every five adults and 300,000 children, arthritis is the nation's leading cause of disability.  The Arthritis Foundation (www.arthritis.org) is committed to raising awareness and reducing the unacceptable impact of this serious and painful disease, which can severely damage joints and rob people of living life to its fullest.  The Foundation funds life-changing research that has restored mobility in patients for more than six decades; fights for health care policies that improve the lives of the millions who live with arthritis; and partners with families to provide empowering programs and information.


'/>"/>
SOURCE Arthritis Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. RI Hospital researchers discover new strategy to effectively treat, prevent osteoarthritis
2. Musculoskeletal Network Features New Research into the Cause of Rheumatoid Arthritis and Lupus
3. Targeting T cells in rheumatoid arthritis
4. WISE Surgical Solutions LLC Announces Project Hope: Helping People with Debilitating Conditions Including Arthritis, Parkinson's, MS and Spinal Injury Know Their Options
5. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
6. Musculoskeletal Network Features Update on Nutraceuticals for Osteoarthritis
7. July is not just about BBQ's; the Arthritis National Research Foundation honors Juvenile Arthritis Awareness Month
8. Riding to Cure Arthritis from New York to Oklahoma
9. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
10. Foundation For the NIH Joins NIH In Seeking Proposals to Study Sports-Related Brain Injuries
11. Physicians Endoscopy and Colon Cancer Challenge Foundation Partner to Raise Colon Cancer Awareness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... Research and Markets has announced the addition of the "Biomarkers: ... The global biomarkers market has grown ... market is expected to grow at a five-year compound annual growth ... billion in 2015 to $96.6 billion in 2020. ... 2020) are discussed. As well, new products approved in 2013 and ...
(Date:6/22/2016)... --  StockNewsNow.com , The Official MicroCap News Source™, today ... Pourhassan , President & CEO of CytoDyn Inc. (OTCQB: ... and potential commercialization of humanized monoclonal antibodies for the ... company,s website (see here: www.CytoDyn.com ). The video ... 2016, at the LD Micro Invitational in ...
(Date:6/22/2016)... , June 22, 2016   ViaCyte, Inc. ... pluripotent stem cell-derived islet replacement therapy for the treatment ... at ISSCR 2016 Annual Meeting.  ISSCR 2016, the Global ... 25th at Moscone West in San Francisco.  ... the presentations are as follows:Event: , Focus Session: Tools ...
(Date:6/22/2016)... , ... June 22, 2016 , ... ... placing a spotlight on immigrant achievements and contributions to North Texas and the ... important contributors from the immigrant community to the civic and economic vitality of ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):